Literature DB >> 27469115

SMAC Mimetic Birinapant plus Radiation Eradicates Human Head and Neck Cancers with Genomic Amplifications of Cell Death Genes FADD and BIRC2.

Danielle F Eytan1,2,3, Grace E Snow1,2, Sophie Carlson1, Adeeb Derakhshan1,2, Anthony Saleh1, Stephen Schiltz1, Hui Cheng1, Suresh Mohan1,2, Shaleeka Cornelius1, Jamie Coupar1, Anastasia L Sowers4, Lidia Hernandez5, James B Mitchell4, Christina M Annunziata5, Zhong Chen1, Carter Van Waes1.   

Abstract

Comparison of tumors from The Cancer Genome Atlas (TCGA) reveals that head and neck squamous cell carcinomas (HNSCC) harbor the most frequent genomic amplifications of Fas-associated death domain (FADD), with or without Baculovirus inhibitor of apoptosis repeat containing BIRC2 (cIAP1), affecting about 30% of patients in association with worse prognosis. Here, we identified HNSCC cell lines harboring FADD/BIRC2 amplifications and overexpression by exome sequencing, RT-PCR, and Western blotting. In vitro, FADD or BIRC2 siRNA knockdown inhibited HNSCC displaying amplification and increased expression of these genes, supporting their functional importance in promoting proliferation. Birinapant, a novel SMAC mimetic, sensitized multiple HNSCC lines to cell death by agonists TNFα or TRAIL and inhibited cIAP1>XIAP>IAP2. Combination of birinapant and TNFα induced sub-G0 DNA fragmentation in sensitive lines and birinapant alone also induced significant G2-M cell-cycle arrest and cell death in UM-SCC-46 cells. Gene transfer and expression of FADD sensitized resistant UM-SCC-38 cells lacking FADD amplification to birinapant and TNFα, supporting a role for FADD in sensitization to IAP inhibitor and death ligands. HNSCC varied in mechanisms of cell death, as indicated by reversal by inhibitors or protein markers of caspase-dependent apoptosis and/or RIPK1/MLKL-mediated necroptosis. In vivo, birinapant inhibited tumor growth and enhanced radiation-induced TNFα, tumor responses, and host survival in UM-SCC-46 and -11B xenograft models displaying amplification and overexpression of FADD+/- BIRC2 These findings suggest that combination of SMAC mimetics such as birinapant plus radiation may be particularly active in HNSCC, which harbor frequent FADD/BIRC2 genomic alterations. Cancer Res; 76(18); 5442-54. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27469115      PMCID: PMC5026594          DOI: 10.1158/0008-5472.CAN-15-3317

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  35 in total

1.  FADD expression is associated with regional and distant metastasis in squamous cell carcinoma of the head and neck.

Authors:  W J Pattje; L J Melchers; L Slagter-Menkema; M F Mastik; M L Schrijvers; J H Gibcus; P M Kluin; O Hoegen-Chouvalova; B F A M van der Laan; J L N Roodenburg; J E van der Wal; E Schuuring; J A Langendijk
Journal:  Histopathology       Date:  2013-06-13       Impact factor: 5.087

2.  Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB activation, and is active in patient-derived xenograft models.

Authors:  Christopher A Benetatos; Yasuhiro Mitsuuchi; Jennifer M Burns; Eric M Neiman; Stephen M Condon; Guangyao Yu; Martin E Seipel; Gurpreet S Kapoor; Matthew G Laporte; Susan R Rippin; Yijun Deng; Mukta S Hendi; Pavan K Tirunahari; Yu-Hua Lee; Thomas Haimowitz; Matthew D Alexander; Martin A Graham; David Weng; Yigong Shi; Mark A McKinlay; Srinivas K Chunduru
Journal:  Mol Cancer Ther       Date:  2014-02-21       Impact factor: 6.261

Review 3.  Nuclear localized phosphorylated FADD induces cell proliferation and is associated with aggressive lung cancer.

Authors:  Mahaveer S Bhojani; Guoan Chen; Brian D Ross; David G Beer; Alnawaz Rehemtulla
Journal:  Cell Cycle       Date:  2005-11-20       Impact factor: 4.534

4.  Phosphorylated FADD induces NF-kappaB, perturbs cell cycle, and is associated with poor outcome in lung adenocarcinomas.

Authors:  Guoan Chen; Mahaveer S Bhojani; Andrew C Heaford; Daniel C Chang; Bharathi Laxman; Dafydd G Thomas; Laura B Griffin; James Yu; Julia M Coppola; Thomas J Giordano; Lin Lin; David Adams; Mark B Orringer; Brian D Ross; David G Beer; Alnawaz Rehemtulla
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-18       Impact factor: 11.205

5.  Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism.

Authors:  Jennifer L Allensworth; Scott J Sauer; H Kim Lyerly; Michael A Morse; Gayathri R Devi
Journal:  Breast Cancer Res Treat       Date:  2012-12-07       Impact factor: 4.872

6.  Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers.

Authors:  Curtis R Pickering; Jiexin Zhang; Suk Young Yoo; Linnea Bengtsson; Shhyam Moorthy; David M Neskey; Mei Zhao; Marcus V Ortega Alves; Kyle Chang; Jennifer Drummond; Elsa Cortez; Tong-Xin Xie; Di Zhang; Woonbok Chung; Jean-Pierre J Issa; Patrick A Zweidler-McKay; Xifeng Wu; Adel K El-Naggar; John N Weinstein; Jing Wang; Donna M Muzny; Richard A Gibbs; David A Wheeler; Jeffrey N Myers; Mitchell J Frederick
Journal:  Cancer Discov       Date:  2013-04-25       Impact factor: 39.397

7.  Genotyping of 73 UM-SCC head and neck squamous cell carcinoma cell lines.

Authors:  J Chad Brenner; Martin P Graham; Bhavna Kumar; Lindsay M Saunders; Robbi Kupfer; Robert H Lyons; Carol R Bradford; Thomas E Carey
Journal:  Head Neck       Date:  2010-04       Impact factor: 3.147

Review 8.  IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer.

Authors:  Mads Gyrd-Hansen; Pascal Meier
Journal:  Nat Rev Cancer       Date:  2010-08       Impact factor: 60.716

9.  Inhibition of transcription factor nuclear factor-kappaB by a mutant inhibitor-kappaBalpha attenuates resistance of human head and neck squamous cell carcinoma to TNF-alpha caspase-mediated cell death.

Authors:  D C Duffey; C V Crowl-Bancroft; Z Chen; F G Ondrey; M Nejad-Sattari; G Dong; C Van Waes
Journal:  Br J Cancer       Date:  2000-11       Impact factor: 7.640

10.  CYLD deubiquitinates RIP1 in the TNFα-induced necrosome to facilitate kinase activation and programmed necrosis.

Authors:  David M Moquin; Thomas McQuade; Francis Ka-Ming Chan
Journal:  PLoS One       Date:  2013-10-02       Impact factor: 3.240

View more
  30 in total

1.  Antagonist of cIAP1/2 and XIAP enhances anti-tumor immunity when combined with radiation and PD-1 blockade in a syngeneic model of head and neck cancer.

Authors:  Roy Xiao; Clint T Allen; Linda Tran; Priya Patel; So-Jin Park; Zhong Chen; Carter Van Waes; Nicole C Schmitt
Journal:  Oncoimmunology       Date:  2018-08-01       Impact factor: 8.110

2.  Dual Antagonist of cIAP/XIAP ASTX660 Sensitizes HPV- and HPV+ Head and Neck Cancers to TNFα, TRAIL, and Radiation Therapy.

Authors:  Roy Xiao; Yi An; Wenda Ye; Adeeb Derakhshan; Hui Cheng; Xinping Yang; Clint Allen; Zhong Chen; Nicole C Schmitt; Carter Van Waes
Journal:  Clin Cancer Res       Date:  2019-07-02       Impact factor: 12.531

3.  Apoptosis-sensitizing activity of birinapant in head and neck squamous cell carcinoma cell lines.

Authors:  Roman C Brands; Mario J J Scheurer; Stefan Hartmann; Axel Seher; Alexander C Kübler; Urs D A Müller-Richter
Journal:  Oncol Lett       Date:  2018-01-12       Impact factor: 2.967

4.  Attenuated TRAF3 Fosters Activation of Alternative NF-κB and Reduced Expression of Antiviral Interferon, TP53, and RB to Promote HPV-Positive Head and Neck Cancers.

Authors:  Jialing Zhang; Tony Chen; Xinping Yang; Hui Cheng; Stephan S Späth; Paul E Clavijo; Jianhong Chen; Christopher Silvin; Natalia Issaeva; Xiulan Su; Wendell G Yarbrough; Christina M Annunziata; Zhong Chen; Carter Van Waes
Journal:  Cancer Res       Date:  2018-06-19       Impact factor: 12.701

Review 5.  Therapeutic Small Molecules Target Inhibitor of Apoptosis Proteins in Cancers with Deregulation of Extrinsic and Intrinsic Cell Death Pathways.

Authors:  Adeeb Derakhshan; Zhong Chen; Carter Van Waes
Journal:  Clin Cancer Res       Date:  2016-12-30       Impact factor: 12.531

6.  LCL161, a SMAC-mimetic, Preferentially Radiosensitizes Human Papillomavirus-negative Head and Neck Squamous Cell Carcinoma.

Authors:  Linlin Yang; Bhavna Kumar; Changxian Shen; Songzhu Zhao; Dukagjin Blakaj; Tianyun Li; Mitchell Romito; Theodoros N Teknos; Terence M Williams
Journal:  Mol Cancer Ther       Date:  2019-04-23       Impact factor: 6.261

7.  Lymphotoxin-β receptor-NIK signaling induces alternative RELB/NF-κB2 activation to promote metastatic gene expression and cell migration in head and neck cancer.

Authors:  Rita Das; Jamie Coupar; Paul E Clavijo; Anthony Saleh; Tsu-Fan Cheng; Xinping Yang; Jianhong Chen; Carter Van Waes; Zhong Chen
Journal:  Mol Carcinog       Date:  2018-11-28       Impact factor: 4.784

8.  WEE1 kinase inhibition reverses G2/M cell cycle checkpoint activation to sensitize cancer cells to immunotherapy.

Authors:  Lillian Sun; Ellen Moore; Rose Berman; Paul E Clavijo; Anthony Saleh; Zhong Chen; Carter Van Waes; John Davies; Jay Friedman; Clint T Allen
Journal:  Oncoimmunology       Date:  2018-07-23       Impact factor: 8.110

9.  Head and Neck Cancers Promote an Inflammatory Transcriptome through Coactivation of Classic and Alternative NF-κB Pathways.

Authors:  Xinping Yang; Hui Cheng; Jianhong Chen; Ru Wang; Anthony Saleh; Han Si; Steven Lee; Emine Guven-Maiorov; Ozlem Keskin; Attila Gursoy; Ruth Nussinov; Jugao Fang; Carter Van Waes; Zhong Chen
Journal:  Cancer Immunol Res       Date:  2019-10-17       Impact factor: 11.151

10.  Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas.

Authors:  Joshua D Campbell; Christina Yau; Reanne Bowlby; Yuexin Liu; Kevin Brennan; Huihui Fan; Alison M Taylor; Chen Wang; Vonn Walter; Rehan Akbani; Lauren Averett Byers; Chad J Creighton; Cristian Coarfa; Juliann Shih; Andrew D Cherniack; Olivier Gevaert; Marcos Prunello; Hui Shen; Pavana Anur; Jianhong Chen; Hui Cheng; D Neil Hayes; Susan Bullman; Chandra Sekhar Pedamallu; Akinyemi I Ojesina; Sara Sadeghi; Karen L Mungall; A Gordon Robertson; Christopher Benz; Andre Schultz; Rupa S Kanchi; Carl M Gay; Apurva Hegde; Lixia Diao; Jing Wang; Wencai Ma; Pavel Sumazin; Hua-Sheng Chiu; Ting-Wen Chen; Preethi Gunaratne; Larry Donehower; Janet S Rader; Rosemary Zuna; Hikmat Al-Ahmadie; Alexander J Lazar; Elsa R Flores; Kenneth Y Tsai; Jane H Zhou; Anil K Rustgi; Esther Drill; Ronglei Shen; Christopher K Wong; Joshua M Stuart; Peter W Laird; Katherine A Hoadley; John N Weinstein; Myron Peto; Curtis R Pickering; Zhong Chen; Carter Van Waes
Journal:  Cell Rep       Date:  2018-04-03       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.